temozolomide has been researched along with Leiomyosarcoma, Epithelioid in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide at the dose schedule employed in the current study was tolerated well and had modest activity against previously treated unresectable or metastatic leiomyosarcoma of both uterine and nonuterine origin." | 9.10 | A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. ( Bagiella, E; Hesdorffer, M; Keohan, ML; Orrico, R; Talbot, SM; Taub, RN; Troxel, AB, 2003) |
| "After obtaining Institutional Review Board approval, we identified women with recurrent leiomyosarcoma treated with temozolomide at MSKCC from 9/2001 to 9/2004." | 8.82 | Temozolomide in uterine leiomyosarcomas. ( Aghajanian, C; Anderson, S, 2005) |
| "To evaluate the anticancer effects of cabozantinib, temozolomide, and their combination in uterine sarcoma cell lines and mouse xenograft models." | 8.12 | Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma. ( Cho, YJ; Choi, JJ; Choi, JY; Hwang, JR; Lee, JW; Noh, JJ; Ryu, JY, 2022) |
| "We studied the mechanisms of sensitivity of soft tissue sarcoma cells to alkylating agent temozolomide." | 7.85 | Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide. ( Boichuk, SV; Khusnutdinov, RR, 2017) |
| "Our objective was to retrospectively review temozolomide in advanced and recurrent uterine leiomyosarcoma and to determine if tumor O-methylguanine DNA methyltransferase (MGMT) expression correlated with clinical response." | 7.76 | Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. ( Atkins, KA; Ferriss, JS; Jazaeri, AA; Lachance, JA; Modesitt, SC, 2010) |
| "Temozolomide at the dose schedule employed in the current study was tolerated well and had modest activity against previously treated unresectable or metastatic leiomyosarcoma of both uterine and nonuterine origin." | 5.10 | A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. ( Bagiella, E; Hesdorffer, M; Keohan, ML; Orrico, R; Talbot, SM; Taub, RN; Troxel, AB, 2003) |
| "After obtaining Institutional Review Board approval, we identified women with recurrent leiomyosarcoma treated with temozolomide at MSKCC from 9/2001 to 9/2004." | 4.82 | Temozolomide in uterine leiomyosarcomas. ( Aghajanian, C; Anderson, S, 2005) |
| "Dacarbazine is an important drug in the therapeutic landscape of leiomyosarcoma (LMS)." | 4.31 | The Impact of O6-Methylguanine-DNA Methyltransferase ( ( Badalamenti, G; Barretta, ML; Buonaiuto, M; Cannella, L; Chiariotti, L; Clemente, O; De Chiara, AR; Della Monica, R; Di Marzo, M; Di Mauro, A; Guida, M; Iervolino, D; Marretta, AL; Tafuto, S; Vincenzi, B, 2023) |
| "To evaluate the anticancer effects of cabozantinib, temozolomide, and their combination in uterine sarcoma cell lines and mouse xenograft models." | 4.12 | Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma. ( Cho, YJ; Choi, JJ; Choi, JY; Hwang, JR; Lee, JW; Noh, JJ; Ryu, JY, 2022) |
| "We studied the mechanisms of sensitivity of soft tissue sarcoma cells to alkylating agent temozolomide." | 3.85 | Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide. ( Boichuk, SV; Khusnutdinov, RR, 2017) |
| "Our objective was to retrospectively review temozolomide in advanced and recurrent uterine leiomyosarcoma and to determine if tumor O-methylguanine DNA methyltransferase (MGMT) expression correlated with clinical response." | 3.76 | Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. ( Atkins, KA; Ferriss, JS; Jazaeri, AA; Lachance, JA; Modesitt, SC, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Noh, JJ | 1 |
| Cho, YJ | 1 |
| Ryu, JY | 1 |
| Choi, JJ | 1 |
| Hwang, JR | 1 |
| Choi, JY | 1 |
| Lee, JW | 1 |
| Cannella, L | 1 |
| Della Monica, R | 1 |
| Marretta, AL | 1 |
| Iervolino, D | 1 |
| Vincenzi, B | 1 |
| De Chiara, AR | 1 |
| Clemente, O | 1 |
| Buonaiuto, M | 1 |
| Barretta, ML | 1 |
| Di Mauro, A | 1 |
| Di Marzo, M | 1 |
| Guida, M | 1 |
| Badalamenti, G | 1 |
| Chiariotti, L | 1 |
| Tafuto, S | 1 |
| Ingham, M | 1 |
| Allred, JB | 1 |
| Chen, L | 1 |
| Das, B | 1 |
| Kochupurakkal, B | 1 |
| Gano, K | 1 |
| George, S | 1 |
| Attia, S | 1 |
| Burgess, MA | 1 |
| Seetharam, M | 1 |
| Boikos, SA | 1 |
| Bui, N | 1 |
| Chen, JL | 1 |
| Close, JL | 1 |
| Cote, GM | 1 |
| Thaker, PH | 1 |
| Ivy, SP | 1 |
| Bose, S | 1 |
| D'Andrea, A | 1 |
| Marino-Enriquez, A | 1 |
| Shapiro, GI | 1 |
| Schwartz, GK | 1 |
| Khusnutdinov, RR | 1 |
| Boichuk, SV | 1 |
| Ferriss, JS | 1 |
| Atkins, KA | 1 |
| Lachance, JA | 1 |
| Modesitt, SC | 1 |
| Jazaeri, AA | 1 |
| Takano, M | 1 |
| Kikuchi, Y | 1 |
| Susumu, N | 1 |
| Kudoh, K | 1 |
| Kita, T | 1 |
| Kouta, H | 1 |
| Goto, T | 1 |
| Furuya, K | 1 |
| Talbot, SM | 1 |
| Keohan, ML | 1 |
| Hesdorffer, M | 1 |
| Orrico, R | 1 |
| Bagiella, E | 1 |
| Troxel, AB | 1 |
| Taub, RN | 1 |
| Anderson, S | 1 |
| Aghajanian, C | 1 |
| Moreno Antón, F | 1 |
| Casado Herraez, A | 1 |
| Puente Vázquez, J | 1 |
| Gómez Díaz, R | 1 |
| Aragoncillo, P | 1 |
| Díaz-Rubio García, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for temozolomide and Leiomyosarcoma, Epithelioid
| Article | Year |
|---|---|
Temozolomide in uterine leiomyosarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; H | 2005 |
2 trials available for temozolomide and Leiomyosarcoma, Epithelioid
| Article | Year |
|---|---|
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Female; Humans; | 2023 |
A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Leiomyosarcoma; Male; M | 2003 |
6 other studies available for temozolomide and Leiomyosarcoma, Epithelioid
| Article | Year |
|---|---|
Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma.
Topics: Anilides; Animals; Apoptosis; Cell Line, Tumor; Female; Humans; Leiomyosarcoma; Mice; Pyridines; Sar | 2022 |
The Impact of O6-Methylguanine-DNA Methyltransferase (
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Methylation; DNA Modificat | 2023 |
Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide.
Topics: Cell Line, Tumor; Cellular Senescence; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; | 2017 |
Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Dacarbazin | 2010 |
Complete remission of recurrent and refractory uterine epithelioid leiomyosarcoma using weekly administration of bevacizumab and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating | 2011 |
Cardiac metastasis from uterine leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidin | 2006 |